Pharmacological Properties of FK886, a New, Centrally Active Neurokinin-1 Receptor Antagonist
スポンサーリンク
概要
- 論文の詳細を見る
The pharmacological properties of the novel neurokinin-1 (NK1) receptor antagonist FK886, ([3,5-bis(trifluoromethyl)phenyl][(2R)-2-(3-hydroxy-4-methylbenzyl)-4-{2-[(2S)-2-(methoxymethyl)morpholin-4-yl]ethyl}piperazin-1-yl]methanone dihydrochloride), were studied. FK886 potently inhibited the binding of [125I]Bolton-Hunter-labeled substance P ([125I]BH-SP; 100 pM) to human NK1 receptors expressed in Chinese hamster ovary (CHO) cells (IC50=0.70 nM). It also possessed high affinities for dog, ferret, gerbil and guinea pig NK1 receptors, but not for rat NK1 receptor. FK886 was highly selective for the NK1 receptor, with 250- and >20000-fold selectivity for human NK1 over NK2 and NK3, respectively. Further, it did not inhibit radioligand binding at 54 different sites, including receptors, ion channels and transporters. FK886 inhibited substance P (3.2 nM)-induced inositol phosphate formation in human NK1 receptor-expressing CHO cells (IC50=1.4 nM) without stimulating NK1 receptors. The antagonism exerted by FK886 against human NK1 receptor was insurmountable in saturation binding experiments, with both the affinity and Bmax of [125I]BH-SP being significantly reduced. After intravenous administration, FK886 (0.01–0.1 mg/kg) dose-dependently inhibited the foot-tapping behavior induced by intracerebroventricular administration of a selective NK1 receptor agonist, GR73632 (10 pmol), in gerbils, with significant inhibition being observed at doses of 0.032–0.1 mg/kg, indicating excellent brain penetration. The brain penetration of FK886 was further demonstrated by the cerebral distribution of radioactivity after intravenous injection of radiolabeled FK886. Taken together, these results demonstrate that FK886 is a potent, highly selective and centrally active, insurmountable antagonist of the NK1 receptor, and suggest that FK886 antagonizes various NK1 receptor-mediated biological effects in the central nervous system.
著者
-
MANDA Toshitaka
Pharmacological Research Laboratories, Fujisawa Pharmaceutical Co., Ltd.
-
Sakuma Hiroyuki
Pharmacology Research Laboratories Astellas Pharma Inc.
-
Yoshino-Furukawa Takako
Pharmacology Research Laboratories, Drug Discovery Research, Astellas Pharma Inc.
-
Yamakuni Hisashi
Pharmacology Research Laboratories, Drug Discovery Research, Astellas Pharma Inc.
-
Maeda Yasue
Pharmacology Research Laboratories, Drug Discovery Research, Astellas Pharma Inc.
-
Kikuchi Aya
Pharmacology Research Laboratories, Drug Discovery Research, Astellas Pharma Inc.
-
Imazumi Katsunori
Pharmacology Research Laboratories, Drug Discovery Research, Astellas Pharma Inc.
-
Sogabe Hajime
Pharmacology Research Laboratories, Drug Discovery Research, Astellas Pharma Inc.
-
Matsuo Masahiko
Pharmacology Research Laboratories, Drug Discovery Research, Astellas Pharma Inc.
-
Uchida Wataru
Pharmacology Research Laboratories, Drug Discovery Research, Astellas Pharma Inc.
-
Manda Toshitaka
Pharmacology Research Laboratories, Drug Discovery Research, Astellas Pharma Inc.
関連論文
- Unique Properties of Coactivator Recruitment Caused by Differential Binding of FK614, an Anti-diabetic Agent, to Peroxisome Proliferator-Activated Receptor γ(Molecular and Cell Biology)
- FK614, a Novel Peroxisome Proliferator-Activated Receptor γ Modulator, Induces Differential Transactivation Through a Unique Ligand-Specific Interaction With Transcriptional Coactivators
- A New Aromatase Inhibitor, FR901537 II.Pharmacological and Antitumor Effects
- Effects of a New Non : Steroidal 5α : Reductase Inhibitor, FK143, on the Prostate Gland in Beagle Dogs
- Pharmacological Properties of FK886, a New, Centrally Active Neurokinin-1 Receptor Antagonist
- Antiemetic Effects of a Potent and Selective Neurokinin-1 Receptor Antagonist, FK886, on Cisplatin- and Apomorphine-Induced Emesis in Dogs
- Comparison of the Effect of the ATP-Sensitive Potassium Channel Opener YM934 With That of Nitroglycerin on Impaired Coronary Circulation in Dogs